The 2021 annual general meeting (AGM) of shareholders of ProQR Therapeutics
will take place on Wednesday, May 19, 2021, at 16:00 hours CET/10:00am EDT.
ARVO 2021 presentation by Stephen R. Russell from Iowa University on the Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in CEP290 mediated Leber Congenital Amaurosis type 10.
The EFF Spring Virtual Summit hosted by ProQR on April 15 is a virtual meeting featuring the latest clinical data for USH2A mediated Usher syndrome and retinitis pigmentosa and a live panel discussion.
Featuring Dr. Byron Lam, Professor, Bascom Palmer Eye Institute, University of Miami School of Medicine
Hosted by Cantor Biotechnology Analysts Emma Nealon, Alethia Young
Company management will present and discuss results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP).
